New York City, NY -- (SBWIRE) -- 01/07/2014 -- To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.
StockMarketIntel.com issues a special report on the following stocks: Hemispherx BioPharma, Inc (NYSEMKT:HEB), Generex Biotechnology Corporation (OTCMKTS:GNBT), Cereplast Inc (OTCMKTS:CERP), North American Palladium Ltd (USA) (NYSEMKT:PAL)
Hemispherx BioPharma, Inc (NYSEMKT:HEB) gained 4.51% recently, while trading on 1.86 million shares, at the price of $0.310. The stock changed hands in a range of $0.30 to $0.34 up till now, bringing its market capitalization at about $52.05 million. If we look at its trading history of the past 52 weeks, the share price suffered a low of $0.18 and was moved to the maximum level of $0.41. Hemispherx Biopharma, Inc. (Hemispherx) is a specialty pharmaceutical company engaged in the clinical development of new drugs therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders. Hemispherx focuses on two core pharmaceutical technology platforms Ampligen and Alferon N Injection.
Why Should Investors Buy HEB After The Recent Gain? Just Go Here and Find Out
Generex Biotechnology Corporation (OTCMKTS:GNBT) added 3.40% recently, in the current trading session, at $0.0395 with a total volume of 2.91 million shares. The stock, on average, trades on a volume of 2.32 million shares. It floated in a range of $0.04 to $0.04 during the recent trading session, with a beta value of 2.12. Its market capitalization now moved to about $22.92 million. In the past 52 weeks, the share price has not declined below $0.02 or above $0.07. Generex Biotechnology Corporation is a Canada-based Company, which develops drug delivery systems and technologies for the treatment of diabetes. The Company has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity. Its buccal insulin spray product, Generex Oral-lyn is in Phase III clinical trials at several sites around the world.
What was the Moving Force behind GNBT on Bullish Run? Read This Research Report
Cereplast Inc (OTCMKTS:CERP) recently recorded a fall of -4.44% and was moving within a range of $0.01-$0.01, its current trading price is $0.0086. The stock is moving up till now with a total volume of 5.55 million shares, versus an average volume of 5.78 million shares. The share price hit its 52-week low of $0.004 and $0.068 was the best price. Cereplast, Inc. (Cereplast) is engaged in developing and commercializing bio-based resins through two product families: Cereplast Compostables Resins, which are compostable, renewable, ecologically sound substitutes for petroleum-based plastics, and Cereplast Sustainables resins (including the Cereplast Hybrid Resins product line), which replaces up to 90% of the petroleum-based content of traditional plastics with materials from renewable resources.
Is it the Right to Grab CERP after the Recent Slump? Get Free Trend Analysis Here
North American Palladium Ltd (USA) (NYSEMKT:PAL) declined -3.33% in its current trading activity, bringing its market capitalization around $171.49 million. The share price, after opening at $0.96, hit a high of $0.96 and hovered above $0.82, while its recent trading price was $0.876. The total number of shares changed hands during the current session up till now was 3.72 million shares, as compared to average trading volume of 3.47 million shares. North American Palladium Ltd. (NAP) is a precious metals producer that has been operating its flagship Lac des Iles mine (LDI) located in Ontario, Canada. LDI is a primary producer of palladium. The Company is in the business of exploring and mining palladium, platinum, gold and certain base metals. The Company’s 100%-owned subsidiary is the Lac des Iles Mines Ltd. (LDI).
Will PAL Reach the Bottom after Yesterday’s Correction? Find Out Here
To receive alerts before the crowd, please take 7 seconds to sign up for our Premium SMS Alerts. Grab your cell phone and text the word "PICKS" to "555888”.
Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our site, or joining our email list.
Neither StockMarketIntel.com, nor its employees and affiliates are registered as investment advisors or broker/dealers in any jurisdiction whatsoever. Through use of this website viewing or using you agree to hold StockMarketIntel.com, its operators, owners, employees, and affiliates harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources that we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. Readers should always do their own due diligence and consult a financial professional. StockMarketIntel.com encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and StockMarketIntel.com makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled company. Any opinions expressed on this website are statements of judgment as of the date of publication and are subject to change without further notice, and may not necessarily be reprinted in future publications or elsewhere.
Read Full disclaimer at: http://stockmarketintel.com/Disclaimer.htm
Copyright © 2005-2014 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)